NCT06748937View on ClinicalTrials.gov

A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions
Tuberculosis
Interventions
DRUG

Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD

Cohort 1 Arm 1

DRUG

Alpibectir 45 mg OD plus Ethionamide 250 mg OD

Cohort 1 Arm 2

DRUG

Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based

Active Comparator

DRUG

Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD

Cohort 2 Arm 4

Trial Locations (1)

7550

RECRUITING

TASK, Cape Town

All Listed Sponsors
collaborator

Innovative Medicines Initiative

OTHER

lead

TASK Applied Science

OTHER